BRAIN Biotech receives EUR 11.51 million milestone payment from Royalty Pharma

RPRX•2026-09-09

Guidance unchanged

Adjusted group EBITDA guidance stays around break-even for the year.

Milestone payment from Royalty Pharma

BRAIN Biotech received a EUR 11.51 million milestone payment from Royalty Pharma tied to deucrictibant development progress.

Clinical progress lifted the likelihood of further regulatory and commercial milestone payments of up to EUR 96.65 million under the Sept. 20, 2024 agreement.

Potential IFRS 9 liability revaluation charge

The company said IFRS 9 liability revaluation may trigger a one-time, non-cash P&L charge of up to EUR 28 million in fiscal 2025/26.

BRAIN Biotech receives EUR 11.51 million milestone payment from Royalty Pharma

Guidance unchanged

Milestone payment from Royalty Pharma

Potential IFRS 9 liability revaluation charge

Related News

Deckers Brands: BMO initiates coverage with underperform rating; target price $70

American Eagle Outfitters, Inc. <AEO.N>: BMO Initiates Coverage With Market Perform Rating; Target Price $18

Ulta Beauty Inc <ULTA.O>: BMO initiates coverage with market perform rating; target price $580

Atlas Lithium contracts 71% of Neves Project direct capex, costs run 16% below DFS estimate

TransUnion study shows 60% of organizations suffer material cyberattack in past 18 months